Secondary amyloidosis epidemiology and demographics

Jump to: navigation, search

Secondary amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Secondary amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Secondary amyloidosis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Secondary amyloidosis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Secondary amyloidosis epidemiology and demographics

CDC on Secondary amyloidosis epidemiology and demographics

Secondary amyloidosis epidemiology and demographics in the news

Blogs on Secondary amyloidosis epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Secondary amyloidosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2] Sahar Memar Montazerin, M.D.[3]

Overview

The incidence of AA amyloidosis is approximately 0.16 per 100,000 individuals in 2008 in the United kingdom. The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries. Secondary amyloidosis more commonly affects children. Men are more commonly affected by amyloidosis than women.

Epidemiology and Demographics

Incidence

  • The incidence of AA amyloidosis is approximately 0.16 per 100,000 individuals in 2008 in the United kingdom.[1]

Prevalence

  • The prevalence of AA amyloidosis is 5,000 to 10,000 per 100,000 individuals with chronic inflammatory process per year worldwide.[2]

Mortality rate

  • The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.[3]

Age

  • Secondary amyloidosis more commonly affects children.[4]

Race

  • There is no racial predilection to secondary amyloidosis.

Gender

  • Men are more commonly affected by amyloidosis than women.[5]

References

  1. Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, Sachchithanantham S, Fontana M, Youngstein T, Quarta CC, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ (September 2017). "Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre". Amyloid. 24 (3): 162–166. doi:10.1080/13506129.2017.1342235. PMID 28686088.
  2. Koivuniemi, Riitta; Paimela, Leena; Suomalainen, Risto; Törnroth, Tom; Leirisalo-Repo, Marjatta (2009). "Amyloidosis is frequently undetected in patients with rheumatoid arthritis". Amyloid. 15 (4): 262–268. doi:10.1080/13506120802524676. ISSN 1350-6129.
  3. Pepys MB (2006). "Amyloidosis". Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.
  4. Bilginer, Yelda; Akpolat, Tekin; Ozen, Seza (2011). "Renal amyloidosis in children". Pediatric Nephrology. 26 (8): 1215–1227. doi:10.1007/s00467-011-1797-x. ISSN 0931-041X.
  5. Shin YM (March 2011). "Hepatic amyloidosis". Korean J Hepatol. 17 (1): 80–3. doi:10.3350/kjhep.2011.17.1.80. PMC 3304630. PMID 21494083.



Linked-in.jpg